Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AY
AYTU BioPharma, Inc. Common Stock
AYTU
Mkt Cap
$22.2M
Volume
29.87K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AY
AYTU
AY
AYTU BioPharma, Inc. Common Stock
AYTU
News
·
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
Mkt Cap
$22.2M
Volume
29.87K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
Elite Pharmaceuticals (ELTP) and Aytu BioPharma (AYTU) are two pharmaceutical companies with CNS and ADHD market exposure, but with different strategies. ELTP focuses on generic pharmaceuticals with an expanding pipeline and strong financial position, while AYTU emphasizes branded medicines centered on its EXXUA growth catalyst. Despite both trading below sector valuations, ELTP is recommended as the better buy due to its broader commercial base, lower execution risk, and improving operating momentum, while AYTU presents a higher-risk turnaround story dependent on EXXUA's success.
Zacks Investment Research · Oct 7, 2026
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Aytu BioPharma reported a Q4 loss of $0.05 per share, beating consensus estimates of -$0.22 loss, representing a 77.27% earnings surprise. The company posted revenues of $16.11 million, surpassing consensus by 39.45%. However, the stock has underperformed the market, down 18.3% year-to-date versus the S&P 500's 13.4% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Zacks Investment Research · Sep 22, 2026
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
HeartSciences Inc. (HSCS) reported a quarterly loss of $0.86 per share, missing the consensus estimate of $0.78 loss by 10.26%. The company posted zero revenues, missing estimates by 97.9%. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market. The Medical Info Systems industry ranks in the top 34% of Zacks industries.
Zacks Investment Research · Sep 14, 2026
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire
The 73rd Emerging Growth Conference is scheduled for July 17-18, 2024, featuring presentations from various companies in the healthcare, technology, and energy sectors.
GlobeNewswire Inc. · Jul 17, 2024
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results. Shapeways Hldgs posted an adjusted loss of $1.36 per share, versus market expectations for a loss of 95 cents per share. The company’s quarterly sales came in at $8.37 million versus estimates of $8.75 million. Shapeways shares fell 20.8% to $2.36 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) shares climbed 62.4% to $2.16 after the company reported third-quarter results. Chemomab Therapeutics Ltd. (NASDAQ: CMMB) shares jumped 55% to $0.9497 after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease. Heron Therapeutics, Inc. (NASDAQ: HRTX) climbed 50.8% to $0.8143 after the company reported mixed third-quarter financial results and issued guidance. Kinnate Biopharma Inc. (NASDAQ: KNTE) rose 47.7% to $2.32. The company’s board of directors received a letter from Foresite Capital Management and OrbiMed Advisors indicating their intent to explore and evaluate a potential acquisition of the company. SciSparc Ltd. (NASDAQ: SPRC) gained 44.5% to $6.30. SciSparc said 'trial results indicated that SciSparc's proprietary SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer's patients who participated.' Evelo Biosciences, Inc. (NASDAQ: EVLO) gained 36% to $0.47. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) climbed 34.3% to $1.75. Solid Biosciences Inc. (NASDAQ: SLDB) shares rose 32.7% to $2.83. Solid Biosciences announced IND clearance by the FDA for duchenne muscular dystrophy gene therapy candidate SGT-003. MGO Global, Inc. (NASDAQ: MGOL) shares climbed 32.4% to $0.6566 after reporting a sharp rise in third-quarter sales. Beyond Air, Inc. (NASDAQ: XAIR) gained 28% to $1.7920. AST SpaceMobile, Inc. (NASDAQ: ASTS) rose 28% to $4.8262 following third-quarter results. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 25.2% to $24.34 after the company reported a ...
Benzinga · Nov 15, 2023
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Baudax Bio, Inc. (NASDAQ: BXRX) gained 109% to $0.6287 after the company announced it was granted orphan drug designation by the FDA for TI-168 for the treatment of Hemophilia A with inhibitors. Chico's FAS, Inc. (NYSE: CHS) shares climbed 61.7% to $7.45 following the announcement of its acquisition by Sycamore Partners for $1 billion. Aditxt, Inc. (NASDAQ: ADTX) gained 57% to $20.47. Axcella Health Inc. (NASDAQ: AXLA) rose 31.3% to $9.08. Inpixon (NASDAQ: INPX) shares gained 23.6% to $0.1729 after gaining around 10% on Wednesday. Soleno Therapeutics, Inc. (NASDAQ: SLNO) jumped 22.2% to $25.25. Soleno Therapeutics reported pricing of approximately $120 million underwritten public offering of common stock and concurrent private placement of common stock and/or pre-funded warrants. Aytu BioPharma, Inc. (NASDAQ: AYTU) gained 22% to $2.33 following fourth-quarter results. Organogenesis Holdings Inc. (NASDAQ: ORGO) gained 20.4% to $3.19. Sarcos Technology and Robotics Corporation (NASDAQ: STRC) gained 20% to $0.80 after the company announced it was awarded a $13.8 million USD contract by the U.S. Air Force for the advancement of its AI and machine learning software. Adamas One Corp. (NASDAQ: JEWL) gained 18% to $0.9200. USA Compression Partners, LP (NYSE: USAC) climbed 14.7% to $25.94. Gritstone bio, Inc. (NASDAQ: GRTS) gained 14.2% to $1.36. Connexa Sports Technologies Inc. (NASDAQ: CNXA) gained 13.7% to $4.08. Connexa Sports Technologies recently announced that it received a letter from the Nasdaq regarding the late filing of its quarterly report. VinFast Auto Ltd. (NASDAQ: VFS) climbed 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Gritstone bio, Inc. (NASDAQ: GRTS) shares rose 13.5% to $1.3550 after the company announced it was awarded a BARDA contract to conduct a Phase 2b comparative study evaluating a next-generation vaccine candidate for COVID-19 valued at ...
Benzinga · Sep 28, 2023
Best Penny Stocks? 4 Hot Stocks With News This Week
Best penny stocks to buy? 4 with news to watch this week The post Best Penny Stocks? 4 Hot Stocks With News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks · Sep 28, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
Upgrades According to B. Riley Securities, the prior rating for Mirati Therapeutics Inc (NASDAQ:MRTX) was changed from Neutral to Buy. In the second quarter, Mirati Therapeutics showed an EPS of $3.04, compared to $3.18 from the year-ago quarter. The stock has a 52-week-high of $101.20 and a 52-week-low of $27.30. At the end of the last trading period, Mirati Therapeutics closed at $27.80. B. Riley Securities upgraded the previous rating for Novavax Inc (NASDAQ:NVAX) from Neutral to Buy. In the second quarter, Novavax showed an EPS of $0.58, compared to $6.53 from the year-ago quarter. At the moment, the stock has a 52-week-high of $62.74 and a 52-week-low of $5.61. Novavax closed at $7.23 at the end of the last trading period. WestPark Capital upgraded the previous rating for WM Technology Inc (NASDAQ:MAPS) from Hold to Buy. WM Tech earned $0.01 in the second quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $3.62 and a 52-week-low of $0.60. WM Tech closed at $1.20 at the end of the last trading period. Berenberg upgraded the previous rating for Marqeta Inc (NASDAQ:MQ) from Hold to Buy. For the second quarter, Marqeta had an EPS of $0.11, compared to year-ago quarter EPS of $0.08. The stock has a 52-week-high of $11.28 and a 52-week-low of $3.46. At the end of the last trading period, Marqeta closed at $4.96. For Chart Industries Inc (NYSE:GTLS), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. Chart Industries earned $1.19 in the second quarter, compared to $0.88 in the year-ago quarter. The current stock performance of Chart Industries shows a 52-week-high of $242.00 and a 52-week-low of $101.44. Moreover, at the end of the last trading period, the closing price was at $165.76. For Golub Capital BDC Inc (NASDAQ:GBDC), Raymond James upgraded the previous rating of Market Perform to Outperform. Golub Capital BDC earned $0.44 in the third quarter, compared to $0.31 in the year-ago quarter. The current stock performance of Golub Capital BDC shows a 52-week-high of $14.50 and a 52-week-low of $11.95. Moreover, at the end of the last trading period, the closing price was at $14.38. According to JP Morgan, the prior rating for DraftKings Inc (NASDAQ:DKNG) was changed from Underweight to Neutral. In the second quarter, DraftKings showed an EPS of $0.14, compared to $0.29 from the year-ago quarter. The stock has a 52-week-high of $34.49 and a 52-week-low of $10.70. At the end of the last trading period, DraftKings closed at $31.71. According to Roth MKM, the prior rating for LivePerson Inc (NASDAQ:LPSN) was changed from Neutral to Buy. For the second quarter, LivePerson had an EPS of $0.12, compared to year-ago quarter EPS of $0.98. At the moment, the stock has a 52-week-high of $18.17 and a 52-week-low of $3.19. LivePerson closed at $3.99 at the end of the last trading period. For Equinor ASA (NYSE:EQNR), RBC Capital upgraded the previous rating of Sector Perform to Outperform. Equinor earned $0.73 in the second quarter, compared to $1.56 in the year-ago quarter. The current stock performance of Equinor shows a 52-week-high of $42.53 and a 52-week-low of $25.23. Moreover, at the end of the last trading period, the closing price was at $30.86. According to Jefferies, the prior rating for Eli Lilly and Co (NYSE:LLY) was changed from Hold to Buy. For the second quarter, Eli Lilly had an EPS of $2.11, compared to year-ago quarter EPS of $1.25. The current stock performance of Eli Lilly shows a 52-week-high of $538.00 and a 52-week-low of $296.34. Moreover, at the end of the last trading period, the closing price was at $521.60. According to Barclays, the prior rating for DISH Network Corp (NASDAQ:DISH) was changed from Underweight to Equal-Weight. In the second quarter, DISH Network showed an EPS of $0.31, compared to $0.82 from the year-ago quarter. The current stock performance of DISH Network shows a 52-week-high of $20.35 and a 52-week-low of $5.83. Moreover, at the end of the last trading period, the closing price was at $8.37. See all analyst ratings upgrades. Downgrades RBC Capital downgraded the previous rating for Calamos Global Dynamic Income Fund (NASDAQ:CHW) from Sector Perform to Underperform. The stock has a 52-week-high of $7.87 and a 52-week-low of $5.33. At the end of the last trading period, Calamos Glb Dynamic closed at $6.09. According to HC Wainwright & Co., the prior rating for Decibel Therapeutics Inc (NASDAQ:DBTX) was changed from Buy to Neutral. For the first quarter, Decibel Therapeutics had an EPS of $0.53, compared to year-ago quarter EPS of $0.56. The current stock performance of Decibel Therapeutics shows a 52-week-high of $5.68 and a 52-week-low of $1.61. Moreover, at the end of the last trading period, the closing price was at $2.79. Northland Capital Markets downgraded the previous rating for Vitesse Energy Inc (NYSE:VTS) from Outperform to Market Perform. Vitesse Energy earned $0.35 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $27.39 and a 52-week-low of $13.90. Vitesse Energy closed at $24.81 at the end of the last trading period. According to BTIG, the prior rating for WeWork Inc (NYSE:WE) was changed from Buy to Neutral. For the second quarter, WeWork had an EPS of $0.21, compared to year-ago quarter EPS of $0.76. At the moment, the stock has a 52-week-high of $5.93 and a 52-week-low of $0.16. WeWork closed at $0.21 at the end of the last trading period. According to Macquarie, the prior rating for PubMatic Inc (NASDAQ:PUBM) was changed from Outperform ...Full story available on Benzinga.com
Benzinga · Aug 9, 2023
Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by over 400 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Aytu BioPharma The Trade: Aytu BioPharma, Inc. (NASDAQ: AYTU) CEO Joshua R Disbrow acquired a total 14,000 shares an average price of $1.86. To acquire ...
Benzinga · Jun 16, 2023
ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of 244.12% and 28.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 8, 2023
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AY
AYTU
AYTU BioPharma, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
AYTU
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any AYTU yet.
Related Tickers
Earnings